BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 30539695)

  • 1. The Plasminogen Activation System Promotes Neurorepair in the Ischemic Brain.
    Yepes M
    Curr Drug Targets; 2019; 20(9):953-959. PubMed ID: 30539695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Cross Talk between Neuronal Urokinase-type Plasminogen Activator (uPA) and Astrocytic uPA Receptor (uPAR) Promotes Astrocytic Activation and Synaptic Recovery in the Ischemic Brain.
    Diaz A; Merino P; Manrique LG; Ospina JP; Cheng L; Wu F; Jeanneret V; Yepes M
    J Neurosci; 2017 Oct; 37(43):10310-10322. PubMed ID: 28931568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urokinase-type plasminogen activator is a modulator of synaptic plasticity in the central nervous system: implications for neurorepair in the ischemic brain.
    Yepes M
    Neural Regen Res; 2020 Apr; 15(4):620-624. PubMed ID: 31638083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urokinase-type plasminogen activator (uPA) promotes ezrin-mediated reorganization of the synaptic cytoskeleton in the ischemic brain.
    Merino P; Diaz A; Manrique LG; Cheng L; Yepes M
    J Biol Chem; 2018 Jun; 293(24):9234-9247. PubMed ID: 29720403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urokinase-type plasminogen activator (uPA) protects the tripartite synapse in the ischemic brain via ezrin-mediated formation of peripheral astrocytic processes.
    Diaz A; Merino P; Manrique LG; Cheng L; Yepes M
    J Cereb Blood Flow Metab; 2019 Nov; 39(11):2157-2171. PubMed ID: 29890880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urokinase-type Plasminogen Activator Induces Neurorepair in the Ischemic Brain.
    Merino P; Yepes M
    J Neurol Exp Neurosci; 2018; 4(2):24-29. PubMed ID: 30417161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urokinase-type plasminogen activator promotes dendritic spine recovery and improves neurological outcome following ischemic stroke.
    Wu F; Catano M; Echeverry R; Torre E; Haile WB; An J; Chen C; Cheng L; Nicholson A; Tong FC; Park J; Yepes M
    J Neurosci; 2014 Oct; 34(43):14219-32. PubMed ID: 25339736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urokinase-type Plasminogen Activator (uPA) Binding to the uPA Receptor (uPAR) Promotes Axonal Regeneration in the Central Nervous System.
    Merino P; Diaz A; Jeanneret V; Wu F; Torre E; Cheng L; Yepes M
    J Biol Chem; 2017 Feb; 292(7):2741-2753. PubMed ID: 27986809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urokinase-type plasminogen activator (uPA) and its receptor (uPAR) promote neurorepair in the ischemic brain.
    Merino P; Diaz A; Yepes M
    Receptors Clin Investig; 2017; 4(2):. PubMed ID: 28804736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The fibrinolytic system: A new target for treatment of depression with psychedelics.
    Idell RD; Florova G; Komissarov AA; Shetty S; Girard RB; Idell S
    Med Hypotheses; 2017 Mar; 100():46-53. PubMed ID: 28236848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator.
    Bugge TH; Flick MJ; Danton MJ; Daugherty CC; Romer J; Dano K; Carmeliet P; Collen D; Degen JL
    Proc Natl Acad Sci U S A; 1996 Jun; 93(12):5899-904. PubMed ID: 8650190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urokinase-type plasminogen activator (uPA) regulates the expression and function of growth-associated protein 43 (GAP-43) in the synapse.
    Merino P; Diaz A; Torre ER; Yepes M
    J Biol Chem; 2020 Jan; 295(2):619-630. PubMed ID: 31819012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urokinase-Type Plasminogen Activator Protects Cerebral Cortical Neurons from Soluble Aβ-Induced Synaptic Damage.
    Diaz A; Merino P; Guo JD; Yepes MA; McCann P; Katta T; Tong EM; Torre E; Rangaraju S; Yepes M
    J Neurosci; 2020 May; 40(21):4251-4263. PubMed ID: 32332118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation and interactions in the activation of cell-associated plasminogen.
    Myöhänen H; Vaheri A
    Cell Mol Life Sci; 2004 Nov; 61(22):2840-58. PubMed ID: 15558213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue plasminogen activator and urokinase plasminogen activator in human epileptogenic pathologies.
    Iyer AM; Zurolo E; Boer K; Baayen JC; Giangaspero F; Arcella A; Di Gennaro GC; Esposito V; Spliet WG; van Rijen PC; Troost D; Gorter JA; Aronica E
    Neuroscience; 2010 May; 167(3):929-45. PubMed ID: 20219643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasminogen Activation System in Rectal Adenocarcinoma.
    Razik E; Kobierzycki C; Grzegrzolka J; Podhorska-Okolow M; Drag-Zalesinska M; Zabel M; Dziegiel P
    Anticancer Res; 2015 Nov; 35(11):6009-15. PubMed ID: 26504024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevation of mRNA levels of tissue-type plasminogen activator and urokinase-type plasminogen activator in hippocampus and cerebral cortex following middle cerebral artery occlusion in rats.
    Ito T; Takenaka K; Sakai H; Yoshimura S; Hayashi K; Noda S; Sakai N
    Neurol Res; 2000 Jun; 22(4):413-9. PubMed ID: 10874693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
    Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG
    Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urokinase-type plasminogen activator supports liver repair independent of its cellular receptor.
    Shanmukhappa K; Sabla GE; Degen JL; Bezerra JA
    BMC Gastroenterol; 2006 Nov; 6():40. PubMed ID: 17134505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epithelial tissue-type plasminogen activator expression, unlike that of urokinase, its receptor, and plasminogen activator inhibitor-1, is increased in chronic venous ulcers.
    Weckroth M; Vaheri A; Virolainen S; Saarialho-Kere U; Jahkola T; Sirén V
    Br J Dermatol; 2004 Dec; 151(6):1189-96. PubMed ID: 15606514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.